<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094765</url>
  </required_header>
  <id_info>
    <org_study_id>XCT4843002</org_study_id>
    <nct_id>NCT05094765</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD</brief_title>
  <official_title>Evaluating Safety and Efficacy of GI-XBI-302 in Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Xbiome Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Xbiome Biotech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether the fecal microbiota transplant (FMT) capsule improves&#xD;
      the response rate of GI-aGVHD in patients with glucocorticoid-refractory acute graft vs. host&#xD;
      disease after allogeneic stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Day 28</time_frame>
    <description>assessed by Overall Response Rate (ORR) at Day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>Day 28</time_frame>
    <description>assessed all related a grade 3 or above adverse event (AE) at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>assessed all related adverse event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shannon index</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>changes of Shannon index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colonization bacteria analysis</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>the number and relative abundance of bacteria that originally existed only in the capsule but could still be detected in the stool samples of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>Kaplan-Meier Curve</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabonomics</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>The changes of calprotectin, Is, SCFA and bile acid were compared</description>
  </other_outcome>
  <other_outcome>
    <measure>biomarkers</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>The changes of IL-6、IL-8、sTNFR1、sST2、Reg3a、Elafin were compared</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemistry</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>The phenotypes and subsets of CD4 and CD8 positive T cells, B cells, NK cells and monocytes were compared</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>Proportion of patients with hormone dosage ≤ 20mg / day equivalent to equivalent converted dose of prednisolone</description>
  </other_outcome>
  <other_outcome>
    <measure>The proportion of patients</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>who stopped antibiotics was compared.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients</measure>
    <time_frame>up to 25 weeks</time_frame>
    <description>Percentage of patients who died due to GVHD</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>GVHD</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 capsules per day for 2 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>Fecal Microbiota Transplantation</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. GVHD within 100 days after allogeneic hematopoietic stem cell transplantation (allo&#xD;
             HSCT);&#xD;
&#xD;
             2. Age 18 - 65 years old, regardless of gender;&#xD;
&#xD;
             3. Patients with grade 3 or 4 gastrointestinal involvement (aGVHD) according to the&#xD;
             International Alliance (Magic) classification standard;&#xD;
&#xD;
             4. Patients with glucocorticoid resistant GI aGVHD are diagnosed. According to the&#xD;
             expert consensus of Chinese allogeneic hematopoietic stem cell transplantation for the&#xD;
             treatment of hematological diseases (III) - acute graft-versus-host disease (2020&#xD;
             Edition), the definition of glucocorticoid resistant acute GVHD is Thomas'&#xD;
             hematopoietic cell transplantation: stem cell transplantation (5th Edition)&#xD;
             Glucocorticoid resistance was defined as PD at 3 days, NR at 7 days or Cr not reached&#xD;
             at 14 days after first-line treatment.&#xD;
&#xD;
             5. ECoG 3 points or less;&#xD;
&#xD;
             6. Stop prophylactic antibiotics at least 12 hours before FMT treatment;&#xD;
&#xD;
             7. Be able and willing to sign informed consent;&#xD;
&#xD;
             8. Patients who are capable of swallowing capsules and can complete the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. There are active but uncontrolled infections, except GVHD complicated with&#xD;
             infectious diarrhea;&#xD;
&#xD;
             2. Gastrointestinal perforation, active gastrointestinal bleeding, small intestinal&#xD;
             obstruction, toxic megacolon or other serious gastrointestinal diseases not caused by&#xD;
             GVHD;&#xD;
&#xD;
             3. Have a history of severe allergic reaction; Or known to be allergic to any&#xD;
             ingredient of intestinal bacteria capsule xbi-302;&#xD;
&#xD;
             4. Any serious disease that can increase the risk of patients participating in the&#xD;
             study;&#xD;
&#xD;
             5. Female subjects with positive pregnancy test and lactation, or female subjects of&#xD;
             childbearing age who refuse to take contraceptive measures during the study;&#xD;
&#xD;
             6. According to the judgment of the researcher, the patients with high dynamic&#xD;
             diarrhea can not stay in the intestine for enough time to dissolve the capsule.&#xD;
&#xD;
             7. HIV, HBV, HCV and syphilis are positive;&#xD;
&#xD;
             8. After colectomy;&#xD;
&#xD;
             9. Participate in other intervention clinical studies within 4 weeks before the&#xD;
             screening period;&#xD;
&#xD;
             10. The expected survival time is less than 12 weeks;&#xD;
&#xD;
             11. The basic body function test is inferior to the following standards: total&#xD;
             neutrophils (neu) &lt; 0.5 (x109 / L), platelet count (PLT) &lt; 30 (x109 / L), serum&#xD;
             creatinine (CR) &gt; 1.5 times the maximum normal value (ULN), albumin (ALB) &lt; 25g / L;&#xD;
&#xD;
             12. There is any situation that the researcher thinks is not suitable for inclusion&#xD;
             (any history of medical history, treatment history or abnormal test data that may&#xD;
             confuse the results of this study, interfere with the subject's whole participation in&#xD;
             the study, or harm the interests of the subject).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yanli zhao</last_name>
    <phone>0316-3306412</phone>
    <email>13121053519@163.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

